Related Experiment Videos
Immunologic classification of lymphoma and lymphoid leukemia
Blood Reviews
|June 1, 1987
Summary
Monoclonal antibodies and gene studies reveal acute lymphoblastic leukemia (ALL) is diverse. These tools help classify non-T-ALL and T-ALL into distinct subgroups, aiding lymphoma subclassification.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Lymphocyte differentiation and lymphoid malignancies are complex.
- Understanding cellular origins is crucial for diagnosis and treatment.
Purpose of the Study:
- To elucidate the heterogeneity of acute lymphoblastic leukemia (ALL).
- To utilize advanced markers for classifying lymphoid malignancies.
Main Methods:
- Employing monoclonal antibodies to identify cell surface antigens.
- Using molecular probes for immunoglobulin and T cell receptor gene analysis.
- Combining these with markers like surface immunoglobulin, sheep erythrocyte receptors, and cytochemical stains.
Main Results:
- Acute lymphoblastic leukemia (ALL) is confirmed as heterogeneous.
- Monoclonal antibodies (e.g., anti-B1, anti-B4) and gene studies show non-T-ALL originates from B lymphocytes, with at least six subgroups identified.
- T-cell acute lymphoblastic leukemia (T-ALL) is classified into three primary subgroups using antibodies like anti-Leu-9 and anti-Leu-1.
- Monoclonal antibodies aid in non-Hodgkin's lymphoma subclassification, correlating with morphology.
Conclusions:
- Monoclonal antibodies and molecular probes are essential for dissecting lymphoid leukemia and lymphoma heterogeneity.
- These markers enable precise subclassification of non-T-ALL, T-ALL, and non-Hodgkin's lymphoma.
- Accurate classification facilitates better understanding and potential therapeutic strategies for lymphoid malignancies.